<code id='FD4BF7581E'></code><style id='FD4BF7581E'></style>
    • <acronym id='FD4BF7581E'></acronym>
      <center id='FD4BF7581E'><center id='FD4BF7581E'><tfoot id='FD4BF7581E'></tfoot></center><abbr id='FD4BF7581E'><dir id='FD4BF7581E'><tfoot id='FD4BF7581E'></tfoot><noframes id='FD4BF7581E'>

    • <optgroup id='FD4BF7581E'><strike id='FD4BF7581E'><sup id='FD4BF7581E'></sup></strike><code id='FD4BF7581E'></code></optgroup>
        1. <b id='FD4BF7581E'><label id='FD4BF7581E'><select id='FD4BF7581E'><dt id='FD4BF7581E'><span id='FD4BF7581E'></span></dt></select></label></b><u id='FD4BF7581E'></u>
          <i id='FD4BF7581E'><strike id='FD4BF7581E'><tt id='FD4BF7581E'><pre id='FD4BF7581E'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:54256
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          VC firm RA Capital starts a new synthetic biology incubator
          VC firm RA Capital starts a new synthetic biology incubator

          AdobeVenturecapitalfirmRACapitalisstartinganewincubator,settingthestageforthefirmtocreatenewstartups

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          HPV vaccine, cervical cancer study delivers historic results

          AnursedeliversadoseoftheHPVvaccineatacollegewesternFranceinOctober2023.DAMIENMEYER/AFPviaGettyImages